Serve a Fundamental Good at Scale

The argument

"When you are a small firm, you can be a good deal shop. But when you want to get large, you have to serve a fundamental good. Otherwise the societal pressure, the government regulation, the forces around you constrain you." Marc Rowan's account of what changes as a financial firm moves from clever to systemic is a constraint argument, not an ethics argument, which is what makes it useful.¹ His claim is mechanical: above a certain size, returns stop being the only variable determining a firm's outcomes. Regulators, legislators, the press, and the public all acquire real standing over the business, and their disposition toward it becomes an actual input into the cost and availability of everything it does. A firm that cannot answer what fundamental good it provides does not get a moral demerit, it gets constrained. The order of operations is the tell: Rowan says he starts with what fundamental good the firm is doing and only then works out the drivers of the business, meaning the legitimacy question comes before strategy rather than being a communications exercise applied afterward.

Apollo's three

Rowan names three fundamental goods Apollo claims to serve: the largest provider of retirement income in the world, against a structural retirement-savings gap in an aging population; the largest source of financing for a broad industrial buildout, infrastructure, energy, next-generation manufacturing, defense, and data centers; and diversification away from increasingly concentrated public markets, the good he says is least understood, since ten stocks now make up close to half of the S&P and are largely levered to the same trend. Each of the three is framed as something society needs and also maps to a line of business that makes money, which is the actual design requirement: a fundamental good that does not overlap the business is a charity, and a business with no fundamental good is a magnet for constraint.

Restated under hostile questioning

The value of hearing the same claim restated while a company's own stock is down roughly 30 percent for the year is that a legitimacy argument under those conditions is either genuinely load-bearing or quietly abandoned. Pressed at a conference during exactly that stretch, Rowan closed an answer about what the firm actually is with a harder version of the same rule: "You don't get to be sizable in the deal business. The deal business can only get so big. You have to serve some fundamental public good. Otherwise you don't get to be big."² Here the good is not only a license to operate, it is a ceiling, and the underlying mechanism gets named directly: "As a deal shop, we don't get to be that big, because although we're doing something from an efficiency point of view, we use up a lot of social capital." Dealmaking produces efficiency and consumes social standing at some exchange rate, and the standing runs out before the capital does, which is the most concrete version of the constraint on record. He maps the same two goods from Apollo's list onto a single structural position, a global retirement crisis pulling from one side and a global industrial buildout from the other, "and we find ourselves in the middle." And he extends the claim past his own firm: "it's not just Apollo. This is the private market firms who have gotten to be size."²

An aggressive version of the same insight

Palmer Luckey's banking venture, Erebor, applies the identical instinct in a more aggressive form: rather than waiting to be constrained and then negotiating compliance, alignment with a stated national interest is built directly into the product from the start, and compliance is offered before it is demanded rather than after.³ Where Rowan describes naming a fundamental good as the price of scale, Luckey's approach treats pre-purchasing legitimacy as a competitive move in its own right rather than only a defensive one.

The obvious objection

A fundamental good is self-nominated, and the party naming it is also the party that benefits from the naming. Apollo's third good, diversification, doubles as its own sales pitch: the diagnosis that public markets can no longer diversify a portfolio and the cure, private assets originated by Apollo, come from the same source. That does not make the diagnosis wrong, and the underlying concentration data is independently checkable, but the framing should be read as a firm explaining why the world needs exactly what it already sells, which does not disqualify the argument so much as it explains why the argument gets made this consistently.